SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
SAREPTA THERAPEUTICS, INC. (SRPT) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $82.74 per share as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-03-02
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $82.74.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $78.66.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $77.01.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $69.05.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $82.74 10-K · filed 2026-03-02 |
| 2024-12-31 | $78.66 10-K · filed 2025-02-28 |
| 2023-12-31 | $77.01 10-K · filed 2024-02-28 |
| 2022-12-31 | $69.05 10-K · filed 2023-02-28 |
| 2021-12-31 | $68.17 10-K · filed 2022-03-01 |
| 2020-12-31 | $68.24 10-K · filed 2021-03-01 |
| 2019-12-31 | $58.65 10-K · filed 2021-03-01 |
| 2018-12-31 | $45.43 10-K · filed 2021-03-01 |
| 2017-12-31 | $28.49 10-K · filed 2020-02-26 |
| 2016-12-31 | $22.83 10-K · filed 2019-02-28 |
| 2015-12-31 | $23.94 10-K · filed 2018-03-01 |
| 2014-12-31 | $23.27 10-K · filed 2017-02-28 |
| 2013-12-31 | $21.50 10-K · filed 2016-02-25 |
| 2013-09-30 | $21.29 10-Q · filed 2013-11-12 |
| 2013-06-30 | $21.27 10-Q · filed 2013-08-08 |
| 2013-03-31 | $13.24 10-Q · filed 2013-05-09 |
| 2012-12-31 | $11.73 10-K · filed 2015-02-26 |
| 2012-09-30 | $10.75 10-Q · filed 2012-11-07 |
| 2012-06-30 | $11.12 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |